LivingGLP1
Study S001511

Efficacy and Safety of Once-weekly Supaglutide Versus Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

ClinicalTrials.gov record

Registration

Registration
NCT04994288
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2; PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
547
Start
2021-08-03
Primary completion
2023-06-20
Lead sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions
Type2 Diabetes
Interventions
BIOLOGICAL:Supaglutide injection; OTHER:placebo injection
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • HbA1c [12 weeks for phase IIb; 24weeks and 52 weeks for phase III]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0004982Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.
Zhu D, Diabetologia
2026Randomized trialPMID 41272211DOIcites ClinicalTrials.gov:NCT04994288; registry reference DERIVED:41272211
R0004911Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus.
Wang Q, Clinical pharmacokinetics
2025Other trialPMID 41107649DOIcites ClinicalTrials.gov:NCT04994288; registry reference DERIVED:41107649
R0006753Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes.
Lou YR, Clinical pharmacokinetics
2025Other trialPMID 39961992DOIcites ClinicalTrials.gov:NCT04994288; registry reference DERIVED:39961992
R0046643757-P: Efficacy and Safety of Supaglutide Monotherapy in Patients with Type 2 Diabetes
QINGHUA WANG, Diabetes
2023Randomized trialDOIcites ClinicalTrials.gov:NCT04994288